A Go-to-Market Strategy Consultant for Medtech Should Bring Surgeon Relationships Before a Launch Plan

Published
October 28, 2026
Last updated
October 28, 2026
Table of contents

A go-to-market strategy consultant for a medtech company should bring the physician network, advisory board, and acquirer relationships a launch depends on. Most founders hire someone who delivers a plan.

The founders who exited well on The State of MedTech did the first, and they started years before launch.

Kevin Rocco of BioRez and Ray Cohen of Axonics each described that sequence on the show.

Key Takeaways

  • Kevin Rocco built a surgeon advisory board during BioRez design development, years before launch. ConMed later bought BioRez in a deal worth up to $250M.
  • Rocco hired David Hook, a VP of sales from Rotation Medical with a surgeon network, to run commercial.
  • Ray Cohen hired about 100 salespeople before Axonics had FDA approval and paid reps $20,000 a month to train. The first quarter on the market brought in $26 million of product.
  • By the time Boston Scientific moved on Axonics, its familiarity with the company had spread across the CFO, R&D, commercial, and legal teams.
  • A consultant worth hiring can name the physicians they'll introduce in six months, the advisory board they'll build, and the commercial hires they'll source.

What Does a Go-to-Market Strategy Consultant Do for a Medtech Company?

Ornate brass key above a lock with a mismatched shape on a navy-blue gradient

A go-to-market strategy consultant for medtech should build the surgeon advisory board, the physician relationships, and the commercial hires a launch depends on. The plan document comes out of that work.

Founders who buy the document alone pay for a deliverable and wait for results that don't arrive.

I keep hearing the same story. A founder hired a consultant and spent six figures on a launch plan. 18 months later, the first surgeon meetings still hadn't happened.

I interviewed Kevin Rocco, founder and CEO of BioRez, on an episode about the BioRez exit.

I asked how he found his early adopters. He said:

"The first thing is you have to get started way, way, way before you go commercial. Years before we were commercial, we had put together a surgeon advisory board that participated in design development, the testing of it, the animal studies, the results. Not only did that allow us to get their valuable input on the process, understanding what the market really wanted, but it also created trust in the data and in the product, so that we had some champions when we did launch."

That board did two jobs before BioRez sold a single unit. It shaped the product, and it gave the company surgeons who already trusted the data.

A launch plan can't produce that. It takes someone who knows which surgeons belong on the board and can get them in the room.

For the full deal, read the BioRez ConMed acquisition breakdown.

How Do You Choose a Go-to-Market Strategy Consultant for a Medtech Startup?

Glass slide on a wooden easel under a spotlight on an empty stage

Ask these questions before you sign. Which physicians will you personally introduce in the first six months? What advisory board will you help build? Which commercial hires will you source?

A consultant who can't name people is learning your category on your budget.

Those questions test the one thing a medtech founder can't buy later, a live network in the category you're entering. A strategy deck from a generalist doesn't come with one.

I think of it as the market-product fit test at the hiring layer.

If the person you're paying already knows the physicians who will decide adoption, they add value from week one. If they don't, you're funding their education.

Rocco ran that test himself. On the same episode, he put it this way:

"I was a first-time CEO, first-time founder, no commercial experience in sports medicine, so I brought in David Hook, who did a very nice job as our vice president of sales, who had a very good network. He was formerly with Rotation Medical."

Rocco didn't hire a consultant for the commercial motion. He hired a VP of sales from an adjacent sports medicine company who already knew the surgeons.

The network was the strategy.

In my experience working with medtech founders, most go the other way and shop for the best-looking plan.

If your gap is the sales leader, read what founders get wrong when hiring their first sales reps.

Medtech GTM Consulting Has to Start Years Before FDA Clearance

Tall wooden hourglass balanced on a stone ledge with its sand nearly drained

Medtech GTM consulting has to start years before FDA clearance. The relationships and the trained commercial team a launch needs can't be built in the quarter the device clears.

FDA clearance is the starting line, not the finish line. Clinical validation ≠ commercial traction.

Axonics shows what that looks like. The company didn't wait for approval to build its commercial team, and the Boston Scientific deal followed years of groundwork.

I interviewed Ray Cohen, who was CEO of Axonics when Boston Scientific bought it for $3.7 billion, on an episode about the Axonics exit.

When people asked what the IPO money was for, he told them approval was about a year away:

"In the meantime, what we're going to do is take this money and hire a hundred salespeople, and they're going to be ready to rock and roll. So the day that we get FDA approval, 100 reps are going to enter the field to compete against Medtronic."

He said Axonics paid reps $20,000 a month to train in 2019, as guaranteed income.

The first quarter on the market sold $26 million of product, even with COVID holding it back.

The acquirer side ran on the same clock. I covered it on a solo episode about 7 lessons from $17B in medtech exits:

"Boston Scientific didn't discover Axonics in 2022. Their familiarity with the company had been built over years through conference conversations, commercial tracking, clinical pressures, their social media presence online, what they were seeing in terms of their go-to-market with patients."

By the time Boston Scientific moved, I said, its familiarity with Axonics was already spread across the CFO, R&D, commercial, and legal teams.

That's why the deal could move faster.

A consultant who starts at launch is late by the length of the pre-commercial window.

For the deal itself, read the Axonics acquisition story. For the gap that opens when the work starts late, read the traction gap framework.

A Go-to-Market Strategy Consultant Has to Teach a Market That Doesn't Know You Yet

Antique gold pocket watch with a cracked crystal and frozen hands on a dark surface

A go-to-market strategy consultant earns the fee by building familiarity with physicians who have never heard of the product. Early-stage medtech categories are undefined in the physician's mind.

Webinars, round tables, and KOL-authored publications close that gap. A conversion report on an audience that doesn't exist yet can't.

So the first job is building the audience, which makes education the consultant's first deliverable.

The right consultant runs that education on a schedule. The wrong one optimizes a funnel for people who don't know the category exists.

Founders who spend the pre-clearance window building physician familiarity arrive at launch with a category that recognizes them. Founders who spend the same window on conversion campaigns arrive with a polished funnel and nobody entering it.

The point came up on an episode about using LinkedIn ads to attract early-adopter surgeons:

"Even if you have a great booth at a conference, you're putting out some content, you have some PR, you'd be surprised how many potential users still don't know about your product."

The advice on that episode was two to three webinars per quarter. The speaker added that it doesn't always have to be a KOL, because someone inside the company can put content out every week.

For the physician side of that work, read how to find key opinion leaders.

What Does This Mean for Medtech Founders Hiring GTM Consulting?

After 400+ episodes of The State of MedTech, the pattern is consistent. Founders who treat this as a document purchase get the document.

The better frame is a hiring decision. The scope tells you which engagement you're buying.

A right-fit scope runs the advisory board through the pre-commercial window and builds physician familiarity quarter over quarter. It cultivates strategic relationships across years and structures the commercial hire around a live network.

A wrong-fit scope ends in a launch plan, a competitive landscape deck, and ICP definitions the sales team files and never opens. It charges for the volume of output.

At MarketCraft, we treat this as market engineering. The network, the board, and the hires come first, and the plan documents what's already working.

For how a full engagement should run week to week, read go-to-market strategy consulting for medtech founders. For the sequence behind it, read the medical device go-to-market strategy.

Frequently Asked Questions

What does a go-to-market strategy consultant do for a medtech company?

A medtech go-to-market strategy consultant builds the advisory board, grows physician relationships across quarters, cultivates strategic acquirer contacts across years, and sources commercial hires from operators with live networks. The launch plan document is a byproduct of that work.

It isn't the main deliverable, and a consultant who stops at the plan has left the hard part undone.

When should a medtech startup hire a go-to-market strategy consultant?

Years before commercial launch. Kevin Rocco's BioRez advisory board operated during design development and animal studies, and Axonics hired and trained its sales force while it waited for FDA approval.

GTM work that starts at launch is late by the length of the pre-commercial window, so the right time is design development, long before clearance.

How do you evaluate a go-to-market strategy consultant?

Ask which physicians and strategic contacts they will personally introduce in the first six months, what advisory board they will help build, and which commercial hires they will source. Vague answers about frameworks are a warning sign.

If the answer is "we'll produce a plan and hand it off," the engagement is a poor fit for a medtech company.

Should a medtech startup hire a consultant or a VP of sales?

It depends on where the gap is. Kevin Rocco had no commercial experience in sports medicine, so he hired a VP of sales from Rotation Medical who already had a surgeon network. When the gap is a commercial leader with relationships, hire the leader.

When the gap is the advisory board and the strategic contacts, a consultant with those relationships fits.

Where Should You Go From Here?

If you're doing this yourself. Read the pillar post on hiring a healthcare marketing agency before defining your category to see the category work that should come before any outside hire. Then listen to The State of MedTech for the founders who did it.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. It checks whether your gap sits upstream in the category or downstream in sales.

Listen to the Full Conversations

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth.

Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.

Copied!